LAG3 and cutaneous mastocytosis: By contrast, patients with CM were characterized by exhausted CD8+ T cells that expressed high level of LAG3 and CTLA4. This implied that the combination of LAG3 and CTLA4 inhibitors might be more appropriate for CM patients.